tbuckley/cabot-search huggingface dataset:
Abstract C20: Investigating the role of the tumor microenvironment and its role in radiation therapy in pancreatic cancer
Authors: Fiona O'Neill, Gemma Moore, Serena O'Keeffe, Brendan McClean, Gerard McVey, Michael Moriarty, Laura Breen, Martin Clynes
Journal: Cancer Research (2016)

Abstract Pancreatic cancer is the 10th most common cancer in Ireland and the 5th most common cause of death. The 5 year survival rate is approximately 6%, due to late diagnosis by which time usually metastasis has occurred. Despite an increase in research on the disease in recent years very little progress has been made and the development of new, more effective therapies is needed. The role of the tumor microenvironment in the progression of pancreatic cancer is becoming the focus of more and more research. It has been determined that the tumor microenvironment plays a significant role in the progression and invasion of the cancer cells and also plays a role in the resistance of tumor to therapy. Utilizing established pancreatic cell lines and human derived fibroblasts and stellate cells, an indirect co-culture approach has been utilized to investigate the mechanisms by which the fibroblasts and stellate cells in the tumor influence the behavior of the cancer cells. Using the same indirect co-culture approach we have sought to evaluate the role in which these stromal components have in the tumor cells response to radiation therapy. We have utilized single and fractionated doses to determine if the different approaches have varying effects on the proliferation, invasion and colony forming ability of the cancer cells. It is hoped that this in vitro evaluation could be used to inform a better approach to radiation treatment of pancreatic cancer. Citation Format: Fiona O'Neill, Gemma Moore, Serena O'Keeffe, Brendan McClean, Gerard McVey, Michael Moriarty, Laura Breen, Martin Clynes. Investigating the role of the tumor microenvironment and its role in radiation therapy in pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr C20.
Selective Inhibition of Lysophosphatidic Acid Acyltransferase-β by CT32228 Inhibits MAPK and Enhances the Antileukemic Activity of Imatinib in BCR-ABL Expressing Cell Lines Resistant to Imatinib.
Authors: Paul La Rosée, Taiping Jia, Shadmehr Demehri, Peter de Vries, Lynn Bonham, Junia V. Melo, Jack W. Singer, Brian J. Druker, Michael W. Deininger
Journal: Blood (2005)
Abstract 4805: Whole genome sequencing of primary breast cancers and matched distant metastases
Authors: Man-Hung Tang, Malin Dahlgren, Christian Brueffer, Christof Winter, Yilun Chen, Eleonor Olsson, Martin Sjöström, Pär-Ola Bendahl, Emma Niméus-Malmström, Lao H. Saal, Åke Borg, Sofia K. Gruvberger-Saal
Journal: Cancer Research (2015)

Abstract Metastatic disease is the main cause of death for breast cancer patients, but it is still unclear whether primary tumor characteristics are predictive of the metastasis phenotype. Our aim was to investigate, by analyzing chromosomal structural variation, the clonal similarities between primary breast tumors and their matched distant metastases. For 11 patients, we performed low-coverage (∼10x) whole-genome sequencing on 11 primary breast tumors and 13 matched distant metastases to enumerate chromosomal rearrangements. The tumor genomes (n = 24) harbored a median of 85 (range 18-405) chromosomal rearrangements per tumor, with a median of 82 (26-310) in primaries compared to 87 (18-405) in distant metastases. Similarity between tumors was assessed based on presence or absence of chromosomal rearrangements. Concordance between matched primaries and distant metastases from the same patient was high, with a median of 89% rearrangements being shared (range 61-100%). Nearly all of the rearrangements were patient-specific, with very little overlap when comparing all possible pairings of tumors from different patients (median 3%). The tumors exhibited different genomic patterns of rearrangements: some carried events scattered throughout the genome while other tumors had events in densely clustered foci - chromothripsis-like hotspots - at a few chromosomal locations. Irrespective of the type of rearrangement profile of the tumor genomes, the patterns were highly conserved between the primary tumor and metastasis from the same patient, although in general metastases acquired additional rearrangement events. Our study suggests that analysis of structural variation in tumor genomes could be useful for identifying tumor origin, facilitating cancer detection via measurement of rearrangements in circulating tumor DNA, and estimating degree of relatedness between primary tumors and metastases. Moreover, our finding that distant metastases have a close clonal relationship to the primary tumor at the level of chromosomal structure is most consistent with chromosomal rearrangements being early events in breast cancer progression that remain stable during the development from a primary tumor to its distant metastasis. Citation Format: Man-Hung Tang, Malin Dahlgren, Christian Brueffer, Christof Winter, Yilun Chen, Eleonor Olsson, Martin Sjöström, Pär-Ola Bendahl, Emma Niméus-Malmström, Lao H. Saal, Åke Borg, Sofia K. Gruvberger-Saal. Whole genome sequencing of primary breast cancers and matched distant metastases. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4805. doi:10.1158/1538-7445.AM2015-4805
E-tablets to collect research-quality patient-reported data
Authors: A. P. Abernethy, J. Herndon, J. Day, L. Hood, J. Wheeler, M. B. Patwardhan, H. S. Shaw, H. K. Lyerly
Journal: Journal of Clinical Oncology (2007)

6609 Introduction: Programmed wireless notebook computers (e-tablets) can collect review of systems (ROS) data at point of care. Patients complete surveys in the clinic waiting area; a report is generated for the subsequent clinical visit. Are e-tablets a feasible, acceptable method for collecting data directly from patients in an academic cancer clinic? Can they reliably collect other survey data? Methods: We used PACE e-tablets (SOS, Inc.) to administer Functional Assessment of Cancer Therapy (FACT)-G, FACT-B, MD Anderson Symptom Inventory (MDASI), FACIT-Fatigue, and Self Efficacy instruments, in addition to the PACE Patient Care Monitor (PCM) ROS survey. Participants were 66 breast cancer patients in Duke Breast Cancer Clinic. At 4 visits in 6 months, participants completed all electronic and 1 paper survey. Subscales were compared using paired t-tests. Patients completed an electronic survey of satisfaction with PCM. Results: Mean age, 55 (SD 12); 77% Caucasian; 49% no college degree; 68% married; 61% metastatic cancer. Patients strongly supported e-tablets: easy to read (94%), easy to respond to questions (98%), weight of computer comfortable (87%). Satisfaction increased over time: helpful for reporting symptoms (75–88%), would recommend PCM to other patients (87–94%). 75% indicated PCM helped them remember symptoms to discuss with the clinician. Responses to paper and electronic surveys were nearly identical for 3 of 4 FACT-G, and all FACT-B, MDASI, and FACIT-Fatigue subscales (all p&gt;0.31). Responses on FACT-G Social Wellbeing and 4 Self Efficacy subscales differed from paper to electronic (all p&lt;0.006, all electronic scores poorer). Conclusions: Patients are satisfied with e-tablets. E- tablets furnish comparable data to those collected by paper on nearly all scales tested. PCM offers a valid, feasible method for collecting research-quality, clinically relevant data from patients in outpatient academic oncology. No significant financial relationships to disclose.
Cardiovascular risk factors and arterial wall properties in childhood cancer survivors; a long-term follow-up
Authors: M. M. Geenen, E. De Groot, F. E. Van Leeuwen, J. J. Kastelein, P. J. Bakker
Journal: Journal of Clinical Oncology (2004)

8090 Background: Cardiovascular disease is a serious complication of radiotherapy and chemotherapy in childhood cancer survivors. In addition, cardiovascular risk factors, like hypertension (HT), endocrine and metabolic disorders such as growth-hormone deficiency (GHD), hypothyroidism (Thy), gonadal dysfunction and obesity are increased. B and M-mode ultrasound measurement of the arterial wall (intima-media thickness (IMT) and functional parameters like stiffness and compliance) are established surrogate markers for atherosclerosis. Methods: Patients treated for Acute Lymphoblastic Lymphoma (ALL) and nephroblastoma with or without radiotherapy (RT), were compared with a group of siblings. Blood samples were taken for analysis of renal and liver function, glucose, lipid profile, lipoproteins, homocysteine, vitamins, thyroid and gonadal hormones. B- and M-mode ultrasound of different segments of the carotid and femoral wall, to measure IMT and arterial wall properties, was performed. Results: 141 patients and 69 control subjects participated in the study. Mean age was 25.6 (± 5.1) and 26 (± 5.5) years respectively (n.s.). Mean follow-up time since cancer treatment was 20.8 (± 5.4) years. Cardiovascular risk factors were increased in patients (HT n = 8, GHD 8, renal insufficiency 4, diabetes mellitus 1, Thy 4) compared to controls (HT 1, subclinical Thy 2). Diastolic blood pressure was increased in the RT group (74.7 ± 9.7 mm Hg vs 70 ± 8.6, p=.001). An increased BMI and W/H ratio was seen in ALL + RT patients (p <.001). There were no differences in lipid profile or other blood values. Mean IMT and the IMT of the different segments were not different between the groups as well. Analyses of functional parameters between the RT and the control group showed a decrease in pulse pressure (p=.011), delta (p<.001) and diastolic diameter (p=.01), compliance (p=.005) and strain (p=.002). Conclusions: Although cardiovascular risk factors are increased in RT treated patients, IMT is not increased even after 20 years follow-up. There are, however, differences in functional arterial wall properties. The significance of these findings is not yet known. No significant financial relationships to disclose.
Disrupted sleep before gynecologic cancer surgery and increased postoperative pain
Authors: C. E. Wright, D. H. Bovbjerg, S. C. Higgins, J. B. Schnur, G. H. Montgomery, K. Zakashansky, P. Dottino
Journal: Journal of Clinical Oncology (2008)

9555 Background: Despite the best clinical care, pain following gynecologic surgery for cancer is a virtually universal patient experience that can have pervasive negative consequences. Given the sometimes prolonged impact of such pain, and the large variability across patients, additional research on modifiable presurgery risk factors is needed. Recent experimental studies have found that sleep disruption may increase pain sensitivity the next day in healthy volunteers. The possible negative effects of poor sleep prior to cancer surgery have not been investigated despite the likelihood that sleep may be particularly disrupted at that time. We hypothesized that sleep before surgery (at a gynecologic oncology practice) would be disrupted compared with healthy women not anticipating surgery. Within the patient group we further hypothesized that disrupted sleep would predict increased postoperative pain. Methods: Sleep disruption (% of time awake in the sleep period) and sleep duration (minutes asleep) were measured in 52 women (15 patients; 38 healthy comparisons) using an actigraph device for 10 nights, commencing 3 nights before surgery. Pain intensity was measured in the patient group using the Brief Pain Inventory 7 days postsurgery. Statistical analyses included univariate analyses of variance and multiple regression. Results: Sleep disruption but not sleep duration, averaged over the three nights before surgery, was significantly greater in the surgery group compared with the healthy comparison group (F=10.0, p=.003). In the patient group increased pain intensity was predicted by heightened sleep disruption (B=−.86, C.I. −.23 to −.099, p=.0001) and lower sleep duration (B=−.48, C.I. −.03 to −.001, p=.033) when controlling for age, surgery duration, presurgery mood and postoperative sleep. Conclusions: This study is the first to document adverse effects of prior sleep disruption and duration on pain in a clinical oncology context. Future research should explore mechanisms responsible for these effects and examine the impact of interventions to improve sleep prior to surgery. No significant financial relationships to disclose.
Outcome of Elderly Patients with Hodgkin's Disease-Single Centre Experience from Riyadh, Saudi Arabia
Authors: Imran Khan Tailor, Syed Ziauddin A. Zaidi, Ibraheem H Motabi, N F Alshehry, Assem A Elghazaly, Samer Homoud S Almudaibigh, Mubarak S. AlGhamdi, Atta Munawar Gill, Shahid Iqbal, G Murtaza, A Butt
Journal: Blood (2015)
Low Incidence of Cytomegalovirus Infection Associated with Rapid Cell-Mediated Immune Reconstitution after Cord Blood Transplantation Using Full Conditioning Regimen Containing 12Gy Total Body Irradiation.
Authors: Satoshi Takahashi, Jun Ooi, Akira Tomonari, Nobuhiro Tsukada, Takaaki Konuma, Takeshi Kobayashi, Aki Sato, Arinobu Tojo, Nobukazu Watanabe, Hiromitsu Nakauchi, Shigetaka Asano
Journal: Blood (2006)
Outcome of Adult AML at First Relapse Following a Risk-Oriented Strategy: The Northern Italy Leukemia Group (NILG) Experience.
Authors: Irene M. Cavattoni, Enrico Morello, Michael Mian, Elena Oldani, Tamara Intermesoli, Erika Borlenghi, Giuseppe Rossi, Claudia Minotto, Elisabetta Terruzzi, Enrico Maria Pogliani, Ernesta Audisio, Filippo Marmont, Alessandro Rambaldi, Renato Bassan, Sergio Cortelazzo
Journal: Blood (2006)
Polycythemia Vera with Multiple Clones Carrying Different Mutations (L611V, V617F, L611V/V617F) in Exon 14 of JAK2.
Authors: Cédric Cleyrat, Jaroslav Jelinek, François Girodon, Marjorie Boissinot, Thierry Ponge, Jean-Luc Harousseau, Jean-Pierre Issa, Sylvie Hermouet, Sylvie Hermouet
Journal: Blood (2009)
Association of a Bundled-Payment Program With Cost and Outcomes in Full-Cycle Breast Cancer Care
Authors: C. Jason Wang, Skye H. Cheng, Jen-You Wu, Yi-Ping Lin, Wen-Hsin Kao, Chia-Li Lin, Yin-Jou Chen, Shu-Ling Tsai, Feng-Yu Kao, Andrew T. Huang
Journal: JAMA Oncology (2016)

<h3>Importance</h3> Value-driven payment system reform is a potential tool for aligning economic incentives with the improvement of quality and efficiency of health care and containment of cost. Such a payment system has not been researched satisfactorily in full-cycle cancer care. <h3>Objective</h3> To examine the association of outcomes and medical expenditures with a bundled-payment pay-for-performance program for breast cancer in Taiwan compared with a fee-for-service (FFS) program. <h3>Design, Setting, and Participants</h3> Data were obtained from the Taiwan Cancer Database, National Health Insurance Claims Data, the National Death Registry, and the bundled-payment enrollment file. Women with newly diagnosed breast cancer and a documented first cancer treatment from January 1, 2004, to December 31, 2008, were selected from the Taiwan Cancer Database and followed up for 5 years, with the last follow-up data available on December 31, 2013. Patients in the bundled-payment program were matched at a ratio of 1:3 with control individuals in an FFS program using a propensity score method. The final sample of 17 940 patients included 4485 (25%) in the bundled-payment group and 13 455 (75%) in the FFS group. <h3>Main Outcomes and Measures</h3> Rates of adherence to quality indicators, survival rates, and medical payments (excluding bonuses paid in the bundled-payment group). The Kaplan-Meier method was used to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox proportional hazards regression model was used to examine the effect of the bundled-payment program on overall and event-free survival. Sensitivity analysis for bonus payments in the bundled-payment group was also performed. <h3>Results</h3> The study population included 17 940 women (mean [SD] age, 52.2 [10.3] years). In the bundled-payment group, 1473 of 4215 patients (34.9%) with applicable quality indicators had full (100%) adherence to quality indicators compared with 3438 of 12 506 patients (27.5%) with applicable quality indicators in the FFS group (<i>P</i> &lt; .001). The 5-year event-free survival rates for patients with stages 0 to III breast cancer were 84.48% for the bundled-payment group and 80.88% for the FFS group (<i>P</i> &lt; .01). Although the 5-year medical payments of the bundled-payment group remained stable, the cumulative medical payments for the FFS group steadily increased from $16 000 to $19 230 and exceeded pay-for-performance bundled payments starting in 2008. <h3>Conclusions and Relevance</h3> In Taiwan, compared with the regular FFS program, bundled payment may lead to better adherence to quality indicators, better outcomes, and more effective cost-control over time.
Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,
Authors: Martha Q Lacy, Betsy R. LaPlant, Kristina Laumann, Morie A Gertz, Suzanne R Hayman, Francis K Buadi, Angela Dispenzieri, Shaji Kumar, John A. Lust, Stephen Russell, David Dingli, Steven R Zeldenrust, Philip R. Greipp, Rafael Fonseca, P.Leif Bergsagel, Vivek Roy, Keith Stewart, Craig B. Reeder, Robert L Hall, S. Vincent Rajkumar, Joseph R. Mikhael
Journal: Blood (2011)
NK Cells Kill Myeloma Cells By Increasing ER Stress and Decreasing Autophagy Levels. NKG2D and NKP30 Are Involved In These Processes
Authors: Beatriz Martin-Antonio, Amer Najjar, Simon N. Robinson, Claude Chew, Li Sufang, Eric Yvon, Michael W. Thomas, Katy Rezvani, Elizabeth J. Shpall, Nina Shah
Journal: Blood (2013)
Caring for Realistic Infant Simulators Does Not Deter Teenage Pregnancy
Authors: Anita Slomski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Identification of Novel Surface Markers and Targets In Neoplastic Stem Cells In AML and CML: a Flow-Gene-Flow Screen Approach.
Authors: Harald Herrmann, Sabine Cerny-Reiterer, Irina Sadovnik, Viviane Winter, Katharina Blatt, Werner Rabitsch, Wolfgang R. Sperr, Elena De Angelis, Steve Holmes, Peter Valent
Journal: Blood (2010)
Prognostic Impact of Serum Soluble Interleukin-2 Receptor Values Just After Completion of R-CHOP in Diffuse Large B-Cell Lymphoma
Authors: Nobuhiko Yamauchi, Kazunari Aoki, June Takeda, Yuki Funayama, Aiko Kato, Yuichiro Ono, Sumie Tabata, Akiko Matsushita, Noboru Yonetani, Takayuki Ishikawa
Journal: Blood (2012)
Phenotypic and Functional Characterization Of a Novel Immature Hematopoietic Myeloid Suppressive Progenitor Cells Mobilized By G-CSF. Application To Gvhd Treatment
Authors: Marie T Rubio, Maud D'Aveni, Tereza Coman, Julien Rossignol, Julie Bruneau, Flora Zavala, Anne C. Brignier, Felipe Suarez, Mohamad Mohty, Olivier Hermine
Journal: Blood (2013)
AB0819 Indirect Comparison of Urate-Lowering Therapies for Hyperuricemic Patients with or without Gout: Meta-Analysis of Randomized Controlled Trials
Authors: M. Fan, J. Liu, B. Zhao, X. Wu, J. Gu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hyperuricemia is the most significant risk factor for the development of gout, defined as a serum concentration of uric acid at 6.8 mg/dl or greater. Long-term maintenance of serum urate levels below its saturation threshold can reduce the frequency of acute gout flares and resolve the existing tophi. <h3>Objectives</h3> To assess the urate-lowering efficacy and safety of febuxostat, allopurinol and benzbromarone in hyperuricemic patients with or without gout. <h3>Methods</h3> We included all the randomized controlled trials (RCTs) that compared any urate-lowering medication with placebo or head to head. The efficacy outcomes included the proportions of achieving the target urate level (&lt;6.0 mg/dl) at final visit or last 3 visits and the percentage of gout flares during the first 8 weeks. The safety outcomes included total adverse events (AEs), withdrawals due to AEs and serious AEs. A Bayesian network model was used to compare all interventions simultaneously. <h3>Results</h3> Sixteen RCTs (6645 patients) were included in the analysis. All urate-lowering therapies were more likely to achieve the target urate level at final visit and last 3 visits than placebo, but had an inconclusive higher risk of gout flares. Furthermore, all of the febuxostat doses (40, 80, 120, 240 mg/day) had a higher proportion of achieving the target urate level at final visit than allopurinol. With febuxostat dosages increased, more patients achieved the target urate level. Febuxostat 240 mg/day was the most effective drug for serum urate normalization. Regarding safety, there were no significant differences among urate-lowering therapies and placebo for total AEs, withdrawals due to AEs and serious AEs, except that allopurinol had a higher risk of total AEs than febuxostat 120mg/day. <h3>Conclusions</h3> Compared to placebo, all urate-lowering therapies are effective in achieving the target urate level for hyperuricemic patients. Febuxostat is more efficacious than allopurinol for serum urate normalization. <h3>References</h3> Hamburger M, Baraf HS, Adamson TC, 3rd, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. The Physician and sportsmedicine 2011;39(4):98–123. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis care &amp; research 2012;64(10):1431–46. Perez-Ruiz F, Liote F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis and rheumatism 2007;57(7):1324–8. <h3>Disclosure of Interest</h3> None declared